Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth

Bianchi, Roberto; Gilardini, Alessandra; Rodriguez-Menendez, Virginia; Oggioni, N; Canta, A; Colombo, Tina; Michele, Giulia De; Martone, S.; Sfacteria, Alessandra; Piedemonte, Giuseppe; Grasso, Giovanni; Beccaglia, Patrizia; Ghezzi, Pietro; D’Incalci, Maurizio; Lauria, Giuseppe; Cavaletti, Guido

doi:10.1016/j.ejca.2006.09.028

Cited by 53 publications

(34 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to Bianchi et al, 81,82 co-administration of cisplatin and erythropoietin, or carbamylated erythropoietin, partially but significantly prevented the thermal heat hypoalgesia without affecting tumor growth. In regard to human recombinant NGF, co-administrered with cisplatin in the rat, it prevents or delays the impaired proprioception.…”

mentioning

confidence: 99%

Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies

et al. 2009

View full text Add to dashboard Cite

Summary:This review examines recent preclinical research on toxic peripheral neuropathy and potential therapeutic developments. Chemotherapy-induced peripheral neurotoxicity is a major clinical problem because it represents the dose-limiting side effects of a significant number of antineoplastic drugs. Patients are unable to complete full or optimal treatment schedules. The incidence of chemotherapy-induced peripheral neuropathy varies depending on the drugs and schedules used, and this can be quite high, particularly when neurophysiological methods are used to make a diagnosis. However, even when chemotherapy-induced peripheral neuropathy is not a doselimiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. As such, improved understanding of the pathophysiology of chemotherapy-induced neurotoxicity need for animal models is clinically relevant and will assist in the development of future neuroprotective strategies and also in the design of novel chemotherapies with improved toxicity profiles. In this review, the features of animal models of chemotherapy-induced painful neuropathy developed for 20 years, due to the administration of the most widely used drugs, such as platinum drugs, taxanes, and vinca alkaloids, will be discussed. In a second part, data available on neuroprotectants and treatment strategies, evaluated using these previous animal models in the attempt to prevent neuropathic pain, will be summarized.

show abstract

mentioning

confidence: 99%

Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Administration of recombinant Epo could be an effective treatment for both cancer-associated anemia and cisplatin-mediated neurotoxicity. Previous studies have demonstrated that Epo is an effective protectant against cisplatin-induced neurotoxicity (15)(16)(17). Cisplatin chemotherapy is also associated with impairment of cognitive functions that might possibly be related to the damage of brain neurons occasionally leading to encephalopathy and seizures (43,44).…”

Section: Discussionmentioning

confidence: 99%

“…It reduces the severity of diabetic neuropathy in animals (13) and ameliorates nerve function during experimental autoimmune encephalomyelitis (14). Recently, Epo was also shown to protect against cisplatin-mediated peripheral neuropathy (15)(16)(17). Numerous studies identified Epo receptors on the surface of a variety of cancer cells (18)(19)(20)(21) (22).…”

Section: Introductionmentioning

confidence: 99%

Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells

Nowis¹,

Legat²,

Bil³

et al. 2007

Int J Oncol

View full text Add to dashboard Cite

Abstract. Cisplatin, a widely used chemotherapeutic is approved for the management of various solid tumors. Administration of cisplatin is associated with induction of significant toxicities that include neurotoxicity and nephrotoxicity, the latter leading to severe and debilitating anemia. Since erythropoietin, a hematopoietic growth factor that corrects chemotherapy-induced anemia, reduces transfusion requirements and seems to improve the patient's quality of life, has been shown to exert cytoprotective effects we decided to investigate its direct influence on cisplatin-induced neurotoxicity against primary cortical neurons isolated from rats. We observed that pre-treatment of neurons with erythropoietin significantly protects these cells from cisplatin-induced cytotoxicity. These effects correlated with amelioration of cisplatin-mediated activation of ERK1/2 kinases and decreased cleavage of caspase 3. Similarly to erythropoietin, a selective ERK1/2 inhibitor significantly reduced cisplatin-induced cytotoxicity against neuronal cells. Importantly, using the same experimental setting we did not observe any protection from cisplatin cytotoxicity against four established tumor cell lines. Altogether our studies confirm that erythropoietin might be an effective cytoprotective agent that reduces cisplatininduced neurotoxicity.

show abstract

“…Erythropoietin has demonstrated promising results in cisplatin and docetaxel models of CIPN (Bianchi et al, 2007;Cervellini et al, 2010). It is considered as a multifunctional trophic factor with potent activity during erythropoiesis and with a neurotrophic action on several neural cells in the central and peripheral nervous systems.…”

Section: Growth Factorsmentioning

confidence: 99%

Neuropathy Secondary to Chemotherapy: A Real Issue for Cancer Survivors

Cidon¹

2012

Basic Principles of Peripheral Nerve Disorders

View full text Add to dashboard Cite

Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth

Cited by 53 publications

References 45 publications

Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies

Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies

Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells

Neuropathy Secondary to Chemotherapy: A Real Issue for Cancer Survivors

Contact Info

Product

Resources

About